Search

Kimball, Alexa B, Kenneth J Rothman, Gregory Kricorian, David Pariser, Paul S Yamauchi, Alan Menter, Craig F Teller, et al. 2015. “OBSERVE-5: Observational Postmarketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis Final 5-Year Results.”. Journal of the American Academy of Dermatology 72 (1): 115-22.

Enamandram, Monica, and Alexa B Kimball. 2013. “Psoriasis Epidemiology: The Interplay of Genes and the Environment.”. The Journal of Investigative Dermatology 133 (2): 287-9.

Lockwood, Stephen J, Lisette M Prens, and Alexa B Kimball. 2018. “Adverse Reactions to Biologics in Psoriasis.”. Current Problems in Dermatology 53: 1-14.

Reich, Kristian, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, et al. 2017. “Tildrakizumab versus Placebo or Etanercept for Chronic Plaque Psoriasis (reSURFACE 1 and ReSURFACE 2): Results from Two Randomised Controlled, Phase 3 Trials.”. Lancet (London, England) 390 (10091): 276-88.

Kimball, Alexandra B, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Enkeleida Nikaï, Baojin Zhu, et al. 2016. “Impact of Ixekizumab on Psoriasis Itch Severity and Other Psoriasis Symptoms: Results from 3 Phase III Psoriasis Clinical Trials.”. Journal of the American Academy of Dermatology 75 (6): 1156-61.

Kimball, A B, A N Naegeli, E Edson-Heredia, C-Y Lin, C Gaich, E Nikaï, K Wyrwich, and G Yosipovitch. 2016. “Psychometric Properties of the Itch Numeric Rating Scale in Patients With Moderate-to-Severe Plaque Psoriasis.”. The British Journal of Dermatology 175 (1): 157-62.

Kimball, A B, K A Papp, K Reich, M Gooderham, Q Li, N Cichanowitz, C La Rosa, and A Blauvelt. 2020. “Efficacy and Safety of Tildrakizumab for Plaque Psoriasis With Continuous Dosing, Treatment Interruption, Dose Adjustments and Switching from Etanercept: Results from Phase III Studies.”. The British Journal of Dermatology 182 (6): 1359-68.

Papp, K A, K Reich, A Blauvelt, A B Kimball, M Gooderham, S K Tyring, R Sinclair, et al. 2019. “Efficacy of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials at Weeks 12 and 28.”. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (6): 1098-1106.

Kimball, A B, M Augustin, K B Gordon, G G Krueger, D Pariser, S Fakharzadeh, K Goyal, et al. 2018. “Correlation of Psoriasis Activity With Socioeconomic Status: Cross-Sectional Analysis of Patients Enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).”. The British Journal of Dermatology 179 (4): 984-86.

Weiss, Stefan C, Josephine Nguyen, Susan Chon, and Alexa B Kimball. 2005. “A Randomized Controlled Clinical Trial Assessing the Effect of Betamethasone Valerate 0.12% Foam on the Short-Term Treatment of Stasis Dermatitis.”. Journal of Drugs in Dermatology : JDD 4 (3): 339-45.